Posted on April 17th, 2019 by Abhinav Kumar in Pharma R&D
Integrating Chemistry Data Sources Provides Big Benefits
Global pharmaceutical companies and other organizations are increasingly in need of solutions for data management and integration needs. Having fast and convenient access to a range of chemistry resources—from targets mined from the literature to a firm’s own lab data—is a major priority.
Important benefits of integrating chemistry notebook data sources include:
- Saving time and increasing the value of data sources through a streamlined search process
- Finding data more easily due to uniform indexing across integrated sources and applying filtering & navigation tools
The industry is embracing solutions that provide the following benefits with key integration capabilities such as:
- Reaction searches that are integrated with the most popular commercial sources
- An ability to integrate with stockrooms and custom catalogs to design syntheses from reagents available from the stockroom or vendors
- In-house and published data can be used for analytics and predictive models via APIs
A number of companies have recently made announcements around this type of integration. A key example is Lundbeck, which has stated that their intention is to “….further refine our analytical capabilities around drug discovery and get even more value from our existing data by reusing information we’ve generated over the years. The challenge has been to break down our internal data siloes and increase data interoperability so that this could become a reality.”
Reaxys and Reaxys Medical Chemistry, from Elsevier, are serving as the unifying platform to meet these needs. To learn even more about the integration capabilities offered by these solutions, click here for Dr. Matthew Clark’s article that expands upon these features.
Abhinav Kumar recently joined Elsevier as the lead of Chemistry Solutions Marketing. He has previously worked in Life Sciences Strategy at Monitor Deloitte. Abhinav has extensive experience in advising on strategy development for leading UK and global life sciences firms. His specific areas of expertise include new models for drug development, digital strategy for R&D and commercial strategy for pharmaceutical companies and contract manufacturing service providers in the life science sector.
Abhinav holds a doctorate in Nanomedicine and Nanotoxicology from King’s College London and have been awarded with Young Investigator Award from 4 different international organizations within the respiratory medicine domain for my research.
R&D Solutions for Pharma & Life SciencesWe’re happy to discuss your needs and show you how Elsevier’s Solution can help.